1 Outlook 2018: excluding the effects from the acquisition of NxStage.
2 Results 2017: adjusted for impacts from IFRS 15 implementation of €486 M.
3 Net income attributable to shareholders of FMC AG & Co. KGaA.
4 Outlook 2018: including recurring impacts from U.S. Tax Reform in the amount of €140 M - €160 M.
5 Results 2017: Proposal to be approved by the Annual General Meeting on May 17, 2018.
6 Full-time equivalents.
At the end of 2017, around 3.2 million patients received dialysis. According to estimates, the number of people worldwide suffering from chronic kidney failure and requiring dialysis treatment is rising at a relatively constant rate of around 6 % annually. It is expected to reach more than 3.4 million patients in 2018 and approximately 4.9 million by 2025. Social trends contribute to this rise in patient numbers. In Europe and the U.S. in particular, they include the aging population and the increasing incidence of diabetes and hypertension, two illnesses that frequently precede the onset of end-stage renal disease. In developing and emerging countries, the growing population and gradually improved access to dialysis as a result fo increasing wealth are key factors that further boost demand for dialysis products and services. We want to continue to make a significant contribution to meeting this demand in the future.
Based on our strategic core competencies, we set ourselves long-term targets in 2014 with our growth
strategy 2020 ( Vision 2020 ):